Shetty Prathima, Shenai Prashanth, Chatra Laxmikanth, Rao Prasanna Kumar
Department of Oral Medicine and Radiology, Yenepoya Dental College, Yenepoya University, Mangalore, Karnataka, India.
Indian J Dent Res. 2013 May-Jun;24(3):347-50. doi: 10.4103/0970-9290.118001.
Oral submucous fibrosis (OSF) is a chronic condition of the oral cavity which results in permanent disability. A number of studies have proven that the management of premalignant diseases should include antioxidants. Therefore, a study was carried out to evaluate the efficacy of spirulina as an antioxidant adjuvant to corticosteroid injections in the management of 40 oral submucous fibrosis subjects of south Karnataka and north Kerala.
An intervention study was conducted on 40 oral submucous fibrosis cases, 40 patients were divided into two groups, group A (spirulina group) and group B (placebo group). Group A received spirulina 500 mg twice daily and biweekly intralesional steroid injection of Betamethasone 4 mg/ml for 3 months and group B was given placebo capsules twice daily and biweekly intralesional steroid injection of Betamethasone 4 mg/ml for 3 months. The results were analyzed with the paired "t" test and the unpaired "t" test.
Clinical improvements in mouth opening was significant in the posttreatment period in both Spirulina and placebo groups. Both the groups showed statistically significant reduction in burning sensation. However, when both groups were compared, mouth opening and burning sensation was found to be statistically very highly significant in favor of the spirulina group.
Spirulina can bring about clinical improvements in OSF patients. The observed effects suggest that spirulina can be used as an adjuvant therapy in the initial management of OSF patients. However, studies involving larger samples and longer period of treatment follow up are suggested in the future.
口腔黏膜下纤维化(OSF)是一种导致永久性残疾的口腔慢性疾病。多项研究已证实,癌前疾病的治疗应包括抗氧化剂。因此,开展了一项研究,以评估螺旋藻作为抗氧化剂辅助皮质类固醇注射治疗南卡纳塔克邦和北喀拉拉邦40例口腔黏膜下纤维化患者的疗效。
对40例口腔黏膜下纤维化病例进行了一项干预性研究,40例患者分为两组,A组(螺旋藻组)和B组(安慰剂组)。A组患者每天两次服用500毫克螺旋藻,并每两周进行一次病灶内注射4毫克/毫升的倍他米松,持续3个月;B组患者每天两次服用安慰剂胶囊,并每两周进行一次病灶内注射4毫克/毫升的倍他米松,持续3个月。结果采用配对“t”检验和非配对“t”检验进行分析。
螺旋藻组和安慰剂组在治疗后开口度的临床改善均显著。两组的烧灼感均有统计学意义的降低。然而,两组比较时,发现开口度和烧灼感在统计学上极显著有利于螺旋藻组。
螺旋藻可使OSF患者获得临床改善。观察到的效果表明,螺旋藻可作为OSF患者初始治疗的辅助疗法。然而,建议未来开展涉及更大样本量和更长治疗随访期的研究。